These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 16504915)

  • 1. Intravenous immunoglobulin in autoimmune disorders: an insight into the immunoregulatory mechanisms.
    Bayry J; Dasgupta S; Misra N; Ephrem A; Duong Van Huyen JP; Delignat S; Hassan G; Caligiuri G; Nicoletti A; Lacroix-Desmazes S; Kazatchkine MD; Kaveri S
    Int Immunopharmacol; 2006 Apr; 6(4):528-34. PubMed ID: 16504915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of natural antibodies in immune homeostasis: IVIg perspective.
    Vani J; Elluru S; Negi VS; Lacroix-Desmazes S; Kazatchkine MD; Bayry J; Kaveri SV
    Autoimmun Rev; 2008 Jun; 7(6):440-4. PubMed ID: 18558359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Regulation of autoreactivity by the idiotypic network and therapeutic modulation of autoimmunity by polyvalent intravenous immunoglobulins (IgIV)].
    Lacroix-Desmazes S; Kaveri S; Kazatchkine MD
    Rev Neurol (Paris); 1996 May; 152(5):349-54. PubMed ID: 8881428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Use of intravenous polyclonal immunoglobulins in autoimmune and inflammatory disorders].
    Graff-Dubois S; Sibéril S; Elluru S; Negi VS; Delignat S; Mouthon L; Lacroix-Desmazes S; Kazatchkine MD; Bayary J; Kaveri SV
    Transfus Clin Biol; 2007 May; 14(1):63-8. PubMed ID: 17498995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and investigational considerations for the use of IGIV therapy.
    Ballow M
    Am J Health Syst Pharm; 2005 Aug; 62(16 Suppl 3):S12-8; quiz S19-21. PubMed ID: 16100383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of autoimmune responses by intravenous immunoglobulin (IVIg).
    Kaveri S; Prasad N; Vassilev T; Hurez V; Pashov A; Lacroix-Desmazes S; Kazatchkine M
    Mult Scler; 1997 Apr; 3(2):121-8. PubMed ID: 9291165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective.
    Sibéril S; Elluru S; Graff-Dubois S; Negi VS; Delignat S; Mouthon L; Lacroix-Desmazes S; Kazatchkine MD; Bayry J; Kaveri SV
    Ann N Y Acad Sci; 2007 Sep; 1110():497-506. PubMed ID: 17911465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Mechanisms of action of intravenous immunoglobulins in the treatment of autoimmune diseases].
    Mouthon L; Hurez V; Kazatchkine M
    Ann Med Interne (Paris); 1993; 144(8):506-13. PubMed ID: 8179238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of cost of immune globulin intravenous therapy to conventional immunosuppressive therapy in treating patients with autoimmune mucocutaneous blistering diseases.
    Daoud YJ; Amin KG
    Int Immunopharmacol; 2006 Apr; 6(4):600-6. PubMed ID: 16504922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action.
    Negi VS; Elluru S; Sibéril S; Graff-Dubois S; Mouthon L; Kazatchkine MD; Lacroix-Desmazes S; Bayry J; Kaveri SV
    J Clin Immunol; 2007 May; 27(3):233-45. PubMed ID: 17351760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of action of intravenous immune globulin in immune-mediated diseases.
    Mouthon L; Kaveri SV; Spalter SH; Lacroix-Desmazes S; Lefranc C; Desai R; Kazatchkine MD
    Clin Exp Immunol; 1996 May; 104 Suppl 1():3-9. PubMed ID: 8625540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of intravenous immunoglobulin therapy in autoimmune blistering diseases.
    Ahmed AR
    Int Immunopharmacol; 2006 Apr; 6(4):557-78. PubMed ID: 16504919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune modulating effects of intravenous immunoglobulin (IVIg) in autoimmune diseases.
    Mouthon L; Kaveri S; Kazatchkine M
    Transfus Sci; 1994 Dec; 15(4):393-408. PubMed ID: 10155557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Normal polyspecific immunoglobulin G (IVIg) in the treatment of autoimmune diseases.
    Hurez V; Kaveri SV; Kazatchkine MD
    J Autoimmun; 1993 Dec; 6(6):675-81. PubMed ID: 8155249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunomodulatory effects of intravenous immunoglobulins].
    Kazatchkine M; Mouthon L; Kaveri SV
    Ann Med Interne (Paris); 2000 May; 151 Suppl 1():1S13-8. PubMed ID: 10896983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of intravenous immunoglobulin therapy in autoimmune and inflammatory disorders.
    Emmi L; Chiarini F
    Neurol Sci; 2002 Apr; 23 Suppl 1():S1-8. PubMed ID: 12032582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous immunoglobulins induce potentially synergistic immunomodulations in autoimmune disorders.
    Imbach P; Lazarus AH; Kühne T
    Vox Sang; 2010 Apr; 98(3 Pt 2):385-94. PubMed ID: 19821958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous immunoglobulin (IVIg) in the treatment of autoimmune and inflammatory diseases.
    Ruiz de Souza V; Kaveri SV; Kazatchkine MD
    Clin Exp Rheumatol; 1993; 11 Suppl 9():S33-6. PubMed ID: 8354005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous IgG: biological modulating molecules.
    Luzi G; Bongiorno F; Paparo Barbaro S; Bruno G
    J Biol Regul Homeost Agents; 2009; 23(1):1-9. PubMed ID: 19321040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous immunoglobulin in autoimmune and inflammatory diseases: more than mere transfer of antibodies.
    Sibéril S; Elluru S; Negi VS; Ephrem A; Misra N; Delignat S; Bayary J; Lacroix-Desmazes S; Kazatchkine MD; Kaveri SV
    Transfus Apher Sci; 2007 Aug; 37(1):103-7. PubMed ID: 17765663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.